Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
NCT02988843 · Masonic Cancer Center, University of Minnesota · PHASE2 · terminated · last registry update 2020-12-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding Unavailable” | – | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-03Phase 3 first posted: AstraZeneca, Dato-DXd + Capecitabine (NCT05104866)
- 2021-10-01Phase 3 first posted: Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2021-08-06Phase 3 first posted: Children's Oncology Group, Cyclophosphamide + Dactinomycin (NCT04994132)
- 2021-06-03Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT01856192)
- 2021-06-01Results posted on the registry: Takeda, Brentuximab vedotin + Doxorubicin (NCT02979522)
- 2021-05-14Phase 3 first posted: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT04887870)
- 2021-04-13Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03488225)
- 2021-03-16Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT04799275)
- 2021-02-18Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT04759586)
- 2021-01-07Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Enfortumab vedotin (EV) (NCT04700124)
- 2020-12-28Phase 3 first posted: University College, London, Doxorubicin + Bleomycin (NCT04685616)
- 2020-12-23Results posted on the registry: OHSU Knight Cancer Institute, Cabazitaxel + Enzalutamide (NCT02522715)
- 2020-11-16Phase 3 first posted: National Cancer Institute (NCI), Cisplatin + Doxorubicin Hydrochloride (NCT04628767)
- 2020-10-08Phase 3 first posted: National Cancer Institute (NCI), Docetaxel + Eribulin Mesylate (NCT04579224)
- 2020-10-06Phase 3 first posted: National Cancer Institute (NCI), Selumetinib Sulfate + Vinblastine Sulfate (NCT04576117)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
- 2020-08-28Phase 3 first posted: Acerta Pharma BV, acalabrutinib + placebo (NCT04529772)
- 2020-05-22Phase 3 first posted: RemeGen Co., Ltd., RC48-ADC + Paclitaxel Injection (NCT04400695)
- 2020-03-13Phase 3 first posted: Mats Heyman, Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses (NCT04307576)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision